Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| non-classical monocyte | 23 studies | 41% ± 16% | |
| classical monocyte | 21 studies | 39% ± 16% | |
| monocyte | 17 studies | 30% ± 12% | |
| conventional dendritic cell | 10 studies | 27% ± 16% | |
| alveolar macrophage | 8 studies | 21% ± 7% | |
| dendritic cell | 7 studies | 27% ± 15% | |
| macrophage | 4 studies | 24% ± 6% | |
| myeloid cell | 3 studies | 28% ± 8% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| peripheral blood | 5 studies | 22% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 100% | 943.89 | 578 / 578 | 75% | 3.74 | 862 / 1155 |
| bladder | 81% | 97.67 | 17 / 21 | 51% | 3.48 | 257 / 504 |
| breast | 54% | 77.24 | 248 / 459 | 47% | 1.30 | 528 / 1118 |
| spleen | 100% | 1568.08 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 20.15 | 1 / 1 |
| intestine | 67% | 98.12 | 646 / 966 | 33% | 0.94 | 174 / 527 |
| esophagus | 47% | 61.93 | 677 / 1445 | 46% | 1.75 | 84 / 183 |
| kidney | 24% | 35.58 | 21 / 89 | 68% | 3.11 | 610 / 901 |
| lymph node | 0% | 0 | 0 / 0 | 90% | 6.50 | 26 / 29 |
| stomach | 50% | 58.95 | 180 / 359 | 40% | 1.09 | 113 / 286 |
| peripheral blood | 86% | 3661.33 | 799 / 929 | 0% | 0 | 0 / 0 |
| skin | 33% | 36.40 | 592 / 1809 | 53% | 1.98 | 250 / 472 |
| pancreas | 13% | 18.10 | 44 / 328 | 71% | 3.11 | 127 / 178 |
| thymus | 32% | 31.30 | 209 / 653 | 50% | 1.18 | 300 / 605 |
| uterus | 42% | 43.98 | 72 / 170 | 37% | 1.43 | 171 / 459 |
| prostate | 59% | 65.60 | 144 / 245 | 20% | 0.34 | 101 / 502 |
| adipose | 77% | 216.66 | 925 / 1204 | 0% | 0 | 0 / 0 |
| liver | 54% | 71.31 | 122 / 226 | 22% | 0.47 | 89 / 406 |
| tonsil | 0% | 0 | 0 / 0 | 62% | 2.53 | 28 / 45 |
| adrenal gland | 46% | 50.26 | 119 / 258 | 10% | 0.17 | 23 / 230 |
| heart | 52% | 73.36 | 444 / 861 | 0% | 0 | 0 / 0 |
| ovary | 10% | 13.41 | 18 / 180 | 38% | 1.01 | 162 / 430 |
| blood vessel | 34% | 53.00 | 449 / 1335 | 0% | 0 | 0 / 0 |
| brain | 3% | 2.12 | 67 / 2642 | 23% | 0.71 | 161 / 705 |
| muscle | 14% | 11.81 | 112 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 9% | 0.18 | 7 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0007165 | Biological process | signal transduction |
| GO_0070821 | Cellular component | tertiary granule membrane |
| GO_0035579 | Cellular component | specific granule membrane |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0004888 | Molecular function | transmembrane signaling receptor activity |
| GO_0030545 | Molecular function | signaling receptor regulator activity |
| GO_0030246 | Molecular function | carbohydrate binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | CLEC12A |
| Protein name | C-type lectin domain family 12 member A Alternative protein CLEC12A C-type lectin domain family 12 member A (C-type lectin-like molecule 1) (CLL-1) (Dendritic cell-associated lectin 2) (DCAL-2) (Myeloid inhibitory C-type lectin-like receptor) (MICL) (CD antigen CD371) |
| Synonyms | DCAL2 MICL CLL1 |
| Description | FUNCTION: Cell surface receptor that modulates signaling cascades and mediates tyrosine phosphorylation of target MAP kinases. . |
| Accessions | ENST00000355690.8 [Q5QGZ9-1] ENST00000350667.4 [Q5QGZ9-4] A8MVL9 ENST00000434319.6 [Q5QGZ9-5] ENST00000396507.7 Q5QGZ9 L8EAV5 ENST00000304361.9 [Q5QGZ9-2] |
